Related Experiment Video
Updated: Jul 9, 2026
Non-invasive Imaging of Acute Allograft Rejection after Rat Renal Transplantation Using 18F-FDG PET
Published on: April 28, 2013
Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib
Angelo Baccala1, Ryan Hedgepeth, Jihad Kaouk
1Cleveland Clinic, Cleveland, Ohio 44195, USA.
Abstract:
Sunitinib is a highly potent, selective vascular endothelial growth factor-receptor types 1 to 3, platelet-derived growth factor (PDGF)-R-alpha, and PDGF-R-ss. Preclinical data suggest that sunitinib (SU11248) has antitumor activity that may result from both inhibition of angiogenesis and direct antiproliferative effects on certain tumor cell types. Sunitinib resulted in tumor shrinkage in 80% of patients who had failed treatment with Bevacizumab and 13% of patients demonstrated an objective Response Evaluation Criteria in solid Tumors (RECIST) in a study presented at the 2006 American Society of Clinical Oncology (ASCO) meeting. We report the first published pathological evidence of sunitinib's effect on recurrent renal cell carcinoma. This was seen in a patient with renal cell carcinoma who developed a renal fossa recurrence 2 years following radical nephrectomy. Tumor shrinkage was evident in the nephrectomy bed after treatment with sunitinib. The pathology of the resected retroperitoneal mass and its implications are discussed.
Insights
Sunitinib demonstrated significant tumor shrinkage in recurrent renal cell carcinoma cases. This study provides pathological evidence of sunitinib
Area of Science:
- Oncology
- Pharmacology
Background:
- Sunitinib is a potent tyrosine kinase inhibitor targeting VEGFR and PDGFR.
- Preclinical data suggest sunitinib has antitumor activity via anti-angiogenesis and direct antiproliferative effects.
Observation:
- A patient with recurrent renal cell carcinoma after nephrectomy received sunitinib treatment.
- Tumor shrinkage was observed in the nephrectomy bed following sunitinib therapy.
Findings:
- This case presents the first published pathological evidence of sunitinib's efficacy in recurrent renal cell carcinoma.
- Sunitinib treatment led to notable tumor reduction in the affected area.
Implications:
- Sunitinib shows promise as a treatment option for advanced or recurrent renal cell carcinoma.
- Pathological examination provides insight into sunitinib's mechanism of action in renal cell carcinoma.
